Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

10.63
-0.4900-4.41%
Post-market: 10.700.0700+0.66%18:00 EDT
Volume:4.49M
Turnover:47.85M
Market Cap:2.74B
PE:3.19
High:11.10
Open:11.04
Low:10.45
Close:11.12
Loading ...

BofA Securities Adjusts Price Target on Organon to $11 From $15, Maintains Underperform Rating

MT Newswires Live
·
Yesterday

Organon Appoints Ramona a. Sequeira to the Company’s Board of Directors

THOMSON REUTERS
·
16 Apr

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors

Business Wire
·
16 Apr

BRIEF-Organon & Co - Expects $6 Million Milestone Expense In Q1 2025

Reuters
·
15 Apr

Press Release: Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

Dow Jones
·
15 Apr

Organon & Co - Expects $6 Million Milestone Expense in Q1 2025

THOMSON REUTERS
·
15 Apr

Health Canada Approves Nduvra™ (Tapinarof Cream), 1%, for the Topical Treatment of Plaque Psoriasis in Adults

THOMSON REUTERS
·
14 Apr

Morgan Stanley Sticks to Its Hold Rating for Organon (OGN)

TIPRANKS
·
09 Apr

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

StockStory
·
08 Apr

Why Organon (OGN) Could Beat Earnings Estimates Again

Zacks
·
03 Apr

Organon Acquires Tofidence for Intravenous Infusion in US

MT Newswires Live
·
01 Apr

Organon & Co - to Pay Tiered Royalties and Milestone Payments to Biogen

THOMSON REUTERS
·
01 Apr

Organon Acquires Tofidence™ (Tocilizumab-Bavi), a Commercialized Biosimilar to Actemra® (Tocilizumab) Injection, for Intravenous Infusion in the U.S.

THOMSON REUTERS
·
01 Apr

Organon & Co - Bio-Thera Solutions to Maintain Manufacturing Rights for Tofidence

THOMSON REUTERS
·
01 Apr

Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug

MT Newswires Live
·
28 Mar

BRIEF-European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX11

Reuters
·
28 Mar

European Medicines Agency (Ema) Validates Henlius and Organon Filing for Perjeta® (Pertuzumab) Biosimilar Candidate Hlx11

THOMSON REUTERS
·
28 Mar

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Business Wire
·
28 Mar

Barclays Sticks to Its Buy Rating for Organon (OGN)

TIPRANKS
·
10 Mar

May Health Appoints Seasoned Medtech Executive, Colby Holtshouse, as President and CEO

THOMSON REUTERS
·
10 Mar